Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
This is a double blind randomized controlled study to evaluate the effect of aldactone on
 peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total
 of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization
 and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on
 peritoneal fibrosis.
Inclusion Criteria:

 -  Age > 18

 -  Hospitalized for peritoneal catheter placement for peritoneal dialysis

 Exclusion Criteria:

 -  Pregnancy

 -  Hiperkalemia (K> 5.5meq/l)

 -  Intolerance to spironolactone